Successful use of trastuzumab deruxtecan in hepatic visceral crisis secondary to metastatic HER2-low breast cancer
•Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and death.•Combination chemotherapy is recommended for hepatic visceral crisis however the outcomes are generally dismal.•Trastuzumab deruxtecan is...
Uloženo v:
| Vydáno v: | Current problems in cancer. Case reports Ročník 20; s. 100392 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Elsevier Inc
01.12.2025
|
| Témata: | |
| ISSN: | 2666-6219, 2666-6219 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and death.•Combination chemotherapy is recommended for hepatic visceral crisis however the outcomes are generally dismal.•Trastuzumab deruxtecan is a recently approved antibody-drug conjugate with high response rates in metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancers.•No guidelines on administration or dose adjustment for trastuzumab deruxtecan are available for severe hepatic impairment.•This case study shows that trastuzumab deruxtecan can be effective in hepatic visceral crisis and further studies should validate its use in this setting.
Hepatic visceral crisis is a life-threatening manifestation of disease progression in 10–20 % of patients with metastatic breast cancer. The condition is defined as a rapid rise in bilirubin > 1.5 times upper limit of normal (ULN) in the absence of biliary tract obstruction or Gilbert’s syndrome. Prompt disease control is required to prevent progression to liver failure and death. There are no standard treatment regimens for hepatic visceral crisis and the prognosis is dismal. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that has recently been approved for patients with metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancer after progression on prior chemotherapy or endocrine therapy. Patients with hepatic visceral crises were not included in any clinical trials for T-DXd and, therefore, no manufacturer-based guidelines on administration or dosing of T-DXd are available in this setting. In this case study, a patient with metastatic HER2-low breast cancer presented with hepatic visceral crisis after progression on two prior lines of endocrine-based therapy. Within a span of days, her total bilirubin had risen to 19 mg/dL and her AST and ALT were both > 15 times ULN. She was offered T-DXd and had rapid, dramatic improvement in her liver chemistries and in her functional status. She received the drug for 25 cycles, resulting in a durable clinical and radiographic response for one and a half years. This case study supports the use of T-DXd in hepatic visceral crisis. Further research should be done to validate its use in this life-threatening setting. |
|---|---|
| AbstractList | •Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and death.•Combination chemotherapy is recommended for hepatic visceral crisis however the outcomes are generally dismal.•Trastuzumab deruxtecan is a recently approved antibody-drug conjugate with high response rates in metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancers.•No guidelines on administration or dose adjustment for trastuzumab deruxtecan are available for severe hepatic impairment.•This case study shows that trastuzumab deruxtecan can be effective in hepatic visceral crisis and further studies should validate its use in this setting.
Hepatic visceral crisis is a life-threatening manifestation of disease progression in 10–20 % of patients with metastatic breast cancer. The condition is defined as a rapid rise in bilirubin > 1.5 times upper limit of normal (ULN) in the absence of biliary tract obstruction or Gilbert’s syndrome. Prompt disease control is required to prevent progression to liver failure and death. There are no standard treatment regimens for hepatic visceral crisis and the prognosis is dismal. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that has recently been approved for patients with metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancer after progression on prior chemotherapy or endocrine therapy. Patients with hepatic visceral crises were not included in any clinical trials for T-DXd and, therefore, no manufacturer-based guidelines on administration or dosing of T-DXd are available in this setting. In this case study, a patient with metastatic HER2-low breast cancer presented with hepatic visceral crisis after progression on two prior lines of endocrine-based therapy. Within a span of days, her total bilirubin had risen to 19 mg/dL and her AST and ALT were both > 15 times ULN. She was offered T-DXd and had rapid, dramatic improvement in her liver chemistries and in her functional status. She received the drug for 25 cycles, resulting in a durable clinical and radiographic response for one and a half years. This case study supports the use of T-DXd in hepatic visceral crisis. Further research should be done to validate its use in this life-threatening setting. Highlights•Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and death. •Combination chemotherapy is recommended for hepatic visceral crisis however the outcomes are generally dismal. •Trastuzumab deruxtecan is a recently approved antibody-drug conjugate with high response rates in metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancers. •No guidelines on administration or dose adjustment for trastuzumab deruxtecan are available for severe hepatic impairment. •This case study shows that trastuzumab deruxtecan can be effective in hepatic visceral crisis and further studies should validate its use in this setting. |
| ArticleNumber | 100392 |
| Author | Su, Malcolm Horadam, Rochelle Klemow, Dawn Kapoor, Nilesh Syed, Samira |
| Author_xml | – sequence: 1 givenname: Nilesh orcidid: 0000-0002-5674-619X surname: Kapoor fullname: Kapoor, Nilesh email: nilesh.kapoor@utsouthwestern.edu organization: Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA – sequence: 2 givenname: Malcolm surname: Su fullname: Su, Malcolm organization: Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA – sequence: 3 givenname: Rochelle surname: Horadam fullname: Horadam, Rochelle organization: Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA – sequence: 4 givenname: Dawn surname: Klemow fullname: Klemow, Dawn organization: Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA – sequence: 5 givenname: Samira surname: Syed fullname: Syed, Samira organization: Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA |
| BookMark | eNqFkdFKAzEQRYNUsNZ-gS_5ga1JNk27iIKUaoWCYPU5ZCezmLrdLclutX69aeuDCFIIJAxz7tzcOSedqq6QkEvOBpxxdbUcwBrADwQTw1hhaSZOSFcopRIleNb59T4j_RCWjMVOzrOR7BK_aAEwhKItaRuQ1gVtvAlN-9WuTE4t-vazQTAVdRV9w7VpHNCNC4DelBS8Cy7QgFBX1vgtbWq6wiby-77Z9FkkZf1Bc4-xRqNM5C7IaWHKgP2fu0de76cvk1kyf3p4nNzNE5Bs1CTCIjAz4jbNR4qpDBVkkqHkueUSUjUWhsVTCJapPMuZFTjOlB1LZYxVwqQ9kh50wdcheCz02rtVdKk507vk9FLvk9O75PQhuUjdHCiM1jYOvQ7gMPq2ziM02tbuCH_7h4fSVQ5M-Y5bDMu69VX8teY6CM30Yreb3WrEMK5FShkFrv8XODr-GzlLpBY |
| Cites_doi | 10.1056/NEJM200103153441101 10.1200/JCO.24.00144 10.1056/NEJMoa052122 10.3390/biomedicines11041083 10.1200/JCO.2009.24.1661 10.1056/NEJMoa1914510 10.1016/j.annonc.2023.05.008 10.1200/JCO.2021.39.15_suppl.1047 10.1016/S1470-2045(17)30604-6 10.1126/science.3798106 10.1111/cas.12966 10.1634/theoncologist.8-4-307 10.3109/07357907.2010.496759 10.1056/NEJMoa2203690 10.1056/NEJMoa2407086 10.1016/j.clinsp.2024.100362 10.1038/s41392-022-00947-7 10.1016/S0140-6736(16)32616-2 10.1038/s41523-020-00208-2 10.1016/j.annonc.2020.09.010 10.1200/JCO.23.02005 10.1200/JCO.2018.77.8738 10.1200/JCO.19.01455 |
| ContentType | Journal Article |
| Copyright | 2025 |
| Copyright_xml | – notice: 2025 |
| DBID | 6I. AAFTH AAYXX CITATION |
| DOI | 10.1016/j.cpccr.2025.100392 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-6219 |
| EndPage | 100392 |
| ExternalDocumentID | 10_1016_j_cpccr_2025_100392 S2666621925000444 1_s2_0_S2666621925000444 |
| GroupedDBID | .1- .FO 0R~ 1P~ AAEDW AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL Z5R 6I. AAFTH AAYXX CITATION |
| ID | FETCH-LOGICAL-c407t-2dec0a71d3b76069e6c940e41bd14c3682a02a0f2096b9b0d2e896d846aad62a3 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001584473600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2666-6219 |
| IngestDate | Sat Nov 29 07:27:50 EST 2025 Sun Oct 19 01:40:49 EDT 2025 Sat Nov 22 12:30:48 EST 2025 Sun Oct 19 01:24:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Metastatic breast cancer HER2-low Trastuzumab deruxtecan Hepatic visceral crisis Antibody-drug conjugate |
| Language | English |
| License | This is an open access article under the CC BY license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c407t-2dec0a71d3b76069e6c940e41bd14c3682a02a0f2096b9b0d2e896d846aad62a3 |
| ORCID | 0000-0002-5674-619X |
| OpenAccessLink | http://dx.doi.org/10.1016/j.cpccr.2025.100392 |
| PageCount | 1 |
| ParticipantIDs | crossref_primary_10_1016_j_cpccr_2025_100392 elsevier_sciencedirect_doi_10_1016_j_cpccr_2025_100392 elsevier_clinicalkeyesjournals_1_s2_0_S2666621925000444 elsevier_clinicalkey_doi_10_1016_j_cpccr_2025_100392 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-12-01 |
| PublicationDateYYYYMMDD | 2025-12-01 |
| PublicationDate_xml | – month: 12 year: 2025 text: 2025-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Current problems in cancer. Case reports |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Modi, Jacot, Yamashita, Sohn, Vidal, Tokunaga (bib0017) 2022; 387 Meric-Bernstam, Makker, Oaknin, Oh, Banerjee, Gonzalez-Martin (bib0016) 2024; 42 Romond, Perez, Bryant, Suman, Geyer, Davidson (bib0020) 2005; 353 Bardia, Hu, Dent, Yonemori, Barrios, O'Shaughnessy (bib0002) 2024; 391 Dawood, Brzozowski (bib0008) 2021; 39 Fu, Li, Han, Shi, Zhang (bib0012) 2022; 7 Benvenuti, Gaudio, Jacobs, Saltalamacchia, De Sanctis, Torrisi (bib0003) 2023; 11 Cardoso, Paluch-Shimon, Senkus, Curigliano, Aapro, Andre (bib0005) 2020; 31 Doi, Shitara, Naito, Shimomura, Fujiwara, Yonemori (bib0009) 2017; 18 Wolff, Hammond, Allison, Harvey, Mangu, Bartlett (bib0026) 2018; 36 Slamon, Leyland-Jones, Shak, Fuchs, Paton, Bajamonde (bib0024) 2001; 344 Higashiyama, Nangia, Shafaee, Chen, Michael, Rimawi (bib0014) 2020; 2 Cameron, Piccart-Gebhart, Gelber, Procter, Goldhirsch, de Azambuja (bib0004) 2017; 389 Ross, Fletcher, Linette, Stec, Clark, Ayers (bib0021) 2003; 8 ENHERTU® (fam-trastuzumab deruxtecan-nxki) [package insert]. Basking Ridge, NJ: daiichi Sankyo, Inc.; 2019. Gianni, Llado, Bianchi, Cortes, Kellokumpu-Lehtinen, Cameron (bib0013) 2010; 28 Damaj, Diab, Freiha, Youddef, Amara, Douaihy (bib0007) 2024; 9 Modi, Saura, Yamashita, Park, Kim, Tamura (bib0018) 2020; 382 Cronin, Harlan, Dodd, Abrams, Ballard-Barbash (bib0006) 2010; 28 Tarantino, Viale, Press, Hu, Penault-Llorca, Bardia (bib0025) 2023; 34 Lu, Mahidin, Azim, Eralp, Yap, Im (bib0015) 2024; 42 Schettini, Chic, Braso-Maristany, Pare, Pascual, Conte (bib0022) 2021; 7 Ogitani, Hagihara, Oitate, Naito, Agatsuma (bib0019) 2016; 107 Fehrenbacher, Cecchini, Geyer, Rastogi, Costantino, Atkins (bib0011) 2020; 38 Slamon, Clark, Wong, Levin, Ullrich, McGuire (bib0023) 1987; 235 Andrade, Bonadio, Diz, Testa (bib0001) 2024; 79 Ogitani (10.1016/j.cpccr.2025.100392_bib0019) 2016; 107 Romond (10.1016/j.cpccr.2025.100392_bib0020) 2005; 353 Fehrenbacher (10.1016/j.cpccr.2025.100392_bib0011) 2020; 38 Modi (10.1016/j.cpccr.2025.100392_bib0018) 2020; 382 Slamon (10.1016/j.cpccr.2025.100392_bib0023) 1987; 235 Slamon (10.1016/j.cpccr.2025.100392_bib0024) 2001; 344 Cardoso (10.1016/j.cpccr.2025.100392_bib0005) 2020; 31 Andrade (10.1016/j.cpccr.2025.100392_bib0001) 2024; 79 Gianni (10.1016/j.cpccr.2025.100392_bib0013) 2010; 28 Meric-Bernstam (10.1016/j.cpccr.2025.100392_bib0016) 2024; 42 10.1016/j.cpccr.2025.100392_bib0010 Bardia (10.1016/j.cpccr.2025.100392_bib0002) 2024; 391 Doi (10.1016/j.cpccr.2025.100392_bib0009) 2017; 18 Fu (10.1016/j.cpccr.2025.100392_bib0012) 2022; 7 Damaj (10.1016/j.cpccr.2025.100392_bib0007) 2024; 9 Dawood (10.1016/j.cpccr.2025.100392_bib0008) 2021; 39 Modi (10.1016/j.cpccr.2025.100392_bib0017) 2022; 387 Ross (10.1016/j.cpccr.2025.100392_bib0021) 2003; 8 Schettini (10.1016/j.cpccr.2025.100392_bib0022) 2021; 7 Benvenuti (10.1016/j.cpccr.2025.100392_bib0003) 2023; 11 Higashiyama (10.1016/j.cpccr.2025.100392_bib0014) 2020; 2 Tarantino (10.1016/j.cpccr.2025.100392_bib0025) 2023; 34 Cronin (10.1016/j.cpccr.2025.100392_bib0006) 2010; 28 Lu (10.1016/j.cpccr.2025.100392_bib0015) 2024; 42 Wolff (10.1016/j.cpccr.2025.100392_bib0026) 2018; 36 Cameron (10.1016/j.cpccr.2025.100392_bib0004) 2017; 389 |
| References_xml | – volume: 11 year: 2023 ident: bib0003 article-title: Clinical Review on the Management of Breast Cancer Visceral Crisis publication-title: Biomedicines – volume: 2 year: 2020 ident: bib0014 article-title: Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases publication-title: Curr. Probl. Cancer – volume: 353 start-page: 1673 year: 2005 end-page: 1684 ident: bib0020 article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer publication-title: N. Engl. J. Med. – volume: 42 start-page: 47 year: 2024 end-page: 58 ident: bib0016 article-title: Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial publication-title: J. Clin. Oncol. – volume: 391 start-page: 2110 year: 2024 end-page: 2122 ident: bib0002 article-title: Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer publication-title: N. Engl. J. Med. – volume: 235 start-page: 177 year: 1987 end-page: 182 ident: bib0023 article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene publication-title: Science – volume: 28 start-page: 1131 year: 2010 end-page: 1137 ident: bib0013 article-title: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer publication-title: J. Clin. Oncol. – volume: 42 start-page: 2812 year: 2024 end-page: 2821 ident: bib0015 article-title: Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/Human epidermal growth factor receptor 2-negative advanced breast cancer publication-title: J. Clin. Oncol. – volume: 9 year: 2024 ident: bib0007 article-title: Life-saving reduced dose of Trastuzumab-deruxtecan in metastatic HER2-low metastatic breast cancer with major hepatic insufficiency: a case report publication-title: Ann. Case. Rep – volume: 344 start-page: 783 year: 2001 end-page: 792 ident: bib0024 article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N. Engl. J. Med. – volume: 107 start-page: 1039 year: 2016 end-page: 1046 ident: bib0019 article-title: Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity publication-title: Cancer. Sci. – volume: 28 start-page: 963 year: 2010 end-page: 968 ident: bib0006 article-title: Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US publication-title: Cancer. Invest. – volume: 18 start-page: 1512 year: 2017 end-page: 1522 ident: bib0009 article-title: Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study publication-title: Lancet. Oncol. – volume: 39 start-page: 1047 year: 2021 ident: bib0008 article-title: Efficacy of CDK4/6i in the visceral crisis setting: result from a real-world database publication-title: J. Clin. Oncol. – volume: 7 start-page: 1 year: 2021 ident: bib0022 article-title: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer publication-title: NPJ. Breast. Cancer. – reference: ENHERTU® (fam-trastuzumab deruxtecan-nxki) [package insert]. Basking Ridge, NJ: daiichi Sankyo, Inc.; 2019. – volume: 79 year: 2024 ident: bib0001 article-title: Visceral crisis in metastatic breast cancer: an old concept with new perspectives publication-title: Clinics – volume: 7 start-page: 93 year: 2022 ident: bib0012 article-title: Antibody drug conjugate: the "biological missile" for targeted cancer therapy publication-title: Signal. Transduct. Target. Ther. – volume: 34 start-page: 645 year: 2023 end-page: 659 ident: bib0025 article-title: ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer publication-title: Ann. Oncol. – volume: 36 start-page: 2105 year: 2018 end-page: 2122 ident: bib0026 article-title: Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline focused update publication-title: J. Clin. Oncol. – volume: 38 start-page: 444 year: 2020 end-page: 453 ident: bib0011 article-title: NSABP B-47/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 publication-title: J. Clin. Oncol. – volume: 387 start-page: 9 year: 2022 end-page: 20 ident: bib0017 article-title: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer publication-title: N. Engl. J. Med. – volume: 8 start-page: 307 year: 2003 end-page: 325 ident: bib0021 article-title: The her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy publication-title: Oncologist – volume: 389 start-page: 1195 year: 2017 end-page: 1205 ident: bib0004 article-title: 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial publication-title: Lancet – volume: 382 start-page: 610 year: 2020 end-page: 621 ident: bib0018 article-title: Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer publication-title: N. Engl. J. Med. – volume: 31 start-page: 1623 year: 2020 end-page: 1649 ident: bib0005 article-title: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) publication-title: Ann. Oncol. – volume: 344 start-page: 783 issue: 11 year: 2001 ident: 10.1016/j.cpccr.2025.100392_bib0024 article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200103153441101 – volume: 42 start-page: 2812 issue: 23 year: 2024 ident: 10.1016/j.cpccr.2025.100392_bib0015 article-title: Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/Human epidermal growth factor receptor 2-negative advanced breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.24.00144 – volume: 353 start-page: 1673 issue: 16 year: 2005 ident: 10.1016/j.cpccr.2025.100392_bib0020 article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa052122 – volume: 11 issue: 4 year: 2023 ident: 10.1016/j.cpccr.2025.100392_bib0003 article-title: Clinical Review on the Management of Breast Cancer Visceral Crisis publication-title: Biomedicines doi: 10.3390/biomedicines11041083 – volume: 28 start-page: 1131 issue: 7 year: 2010 ident: 10.1016/j.cpccr.2025.100392_bib0013 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.24.1661 – volume: 382 start-page: 610 issue: 7 year: 2020 ident: 10.1016/j.cpccr.2025.100392_bib0018 article-title: Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1914510 – volume: 34 start-page: 645 issue: 8 year: 2023 ident: 10.1016/j.cpccr.2025.100392_bib0025 article-title: ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2023.05.008 – volume: 39 start-page: 1047 issue: 15_suppl year: 2021 ident: 10.1016/j.cpccr.2025.100392_bib0008 article-title: Efficacy of CDK4/6i in the visceral crisis setting: result from a real-world database publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.15_suppl.1047 – volume: 18 start-page: 1512 issue: 11 year: 2017 ident: 10.1016/j.cpccr.2025.100392_bib0009 article-title: Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study publication-title: Lancet. Oncol. doi: 10.1016/S1470-2045(17)30604-6 – volume: 235 start-page: 177 issue: 4785 year: 1987 ident: 10.1016/j.cpccr.2025.100392_bib0023 article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene publication-title: Science doi: 10.1126/science.3798106 – volume: 107 start-page: 1039 issue: 7 year: 2016 ident: 10.1016/j.cpccr.2025.100392_bib0019 article-title: Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity publication-title: Cancer. Sci. doi: 10.1111/cas.12966 – volume: 8 start-page: 307 issue: 4 year: 2003 ident: 10.1016/j.cpccr.2025.100392_bib0021 article-title: The her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy publication-title: Oncologist doi: 10.1634/theoncologist.8-4-307 – volume: 28 start-page: 963 issue: 9 year: 2010 ident: 10.1016/j.cpccr.2025.100392_bib0006 article-title: Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US publication-title: Cancer. Invest. doi: 10.3109/07357907.2010.496759 – volume: 387 start-page: 9 issue: 1 year: 2022 ident: 10.1016/j.cpccr.2025.100392_bib0017 article-title: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2203690 – ident: 10.1016/j.cpccr.2025.100392_bib0010 – volume: 391 start-page: 2110 issue: 22 year: 2024 ident: 10.1016/j.cpccr.2025.100392_bib0002 article-title: Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2407086 – volume: 79 year: 2024 ident: 10.1016/j.cpccr.2025.100392_bib0001 article-title: Visceral crisis in metastatic breast cancer: an old concept with new perspectives publication-title: Clinics doi: 10.1016/j.clinsp.2024.100362 – volume: 7 start-page: 93 issue: 1 year: 2022 ident: 10.1016/j.cpccr.2025.100392_bib0012 article-title: Antibody drug conjugate: the "biological missile" for targeted cancer therapy publication-title: Signal. Transduct. Target. Ther. doi: 10.1038/s41392-022-00947-7 – volume: 389 start-page: 1195 issue: 10075 year: 2017 ident: 10.1016/j.cpccr.2025.100392_bib0004 article-title: 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32616-2 – volume: 9 issue: 4 year: 2024 ident: 10.1016/j.cpccr.2025.100392_bib0007 article-title: Life-saving reduced dose of Trastuzumab-deruxtecan in metastatic HER2-low metastatic breast cancer with major hepatic insufficiency: a case report publication-title: Ann. Case. Rep – volume: 7 start-page: 1 issue: 1 year: 2021 ident: 10.1016/j.cpccr.2025.100392_bib0022 article-title: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer publication-title: NPJ. Breast. Cancer. doi: 10.1038/s41523-020-00208-2 – volume: 31 start-page: 1623 issue: 12 year: 2020 ident: 10.1016/j.cpccr.2025.100392_bib0005 article-title: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.09.010 – volume: 42 start-page: 47 issue: 1 year: 2024 ident: 10.1016/j.cpccr.2025.100392_bib0016 article-title: Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.23.02005 – volume: 36 start-page: 2105 issue: 20 year: 2018 ident: 10.1016/j.cpccr.2025.100392_bib0026 article-title: Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline focused update publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.77.8738 – volume: 2 year: 2020 ident: 10.1016/j.cpccr.2025.100392_bib0014 article-title: Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases publication-title: Curr. Probl. Cancer – volume: 38 start-page: 444 issue: 5 year: 2020 ident: 10.1016/j.cpccr.2025.100392_bib0011 article-title: NSABP B-47/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.01455 |
| SSID | ssj0002511974 |
| Score | 2.3109488 |
| Snippet | •Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and... Highlights•Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver... |
| SourceID | crossref elsevier |
| SourceType | Index Database Publisher |
| StartPage | 100392 |
| SubjectTerms | Antibody-drug conjugate Hematology, Oncology, and Palliative Medicine Hepatic visceral crisis HER2-low Metastatic breast cancer Trastuzumab deruxtecan |
| Title | Successful use of trastuzumab deruxtecan in hepatic visceral crisis secondary to metastatic HER2-low breast cancer |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666621925000444 https://www.clinicalkey.es/playcontent/1-s2.0-S2666621925000444 https://dx.doi.org/10.1016/j.cpccr.2025.100392 |
| Volume | 20 |
| WOSCitedRecordID | wos001584473600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2666-6219 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511974 issn: 2666-6219 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2666-6219 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511974 issn: 2666-6219 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Li9swEBbptpReSp9s-lh06C11cBTHso4lTVkoG8pmC3sTsiTThMQOsZ1deuj_7L_pSPJryfYJhWCCkCxF82U0Gn0zQuiNuTVkHCXUA10HDyoDj0mjDHUi_TgJE0Fje9kEnc-jy0v2qdf7XsfC7Nc0TaPra7b9r6KGMhC2CZ39C3E3L4UC-A5ChyeIHZ5_JPhFae9ANNzj0jnqi53Ii_JruRHxQOldaRK3Cstw_KK3NmPrfplL45wagA4xGUpys01WhlAHpulGF8LEHUG909k58dbZ1SA2XPbCUMZkRe9d3cxiWl1UY9m2rtZwMIUVsz6kaBS92GbOYzAH_ZQ3zulF6SKJ1gDUTYM9wKtyCD7PHIW1eQ905o6p3ourtOvLIJMOL8SqPLAWQi-slai-pazS2cTvKN2RCTAmnSW8LThYIJyvYjWUWylNOlgyGXabd9Nxz6YfR15Ohr63MGMwQyATewIe3KzsNlM8J9znB1XvoLuETphRuGffWvcfsee3hvPQ_L46J5ZlHx6M73a7qWMLXTxCD6tNDH7nwPcY9XT6BN0_q2gaT9GuxSAGDOIswR0M4haDeJniCoO4xiB2GMQNBnGR4RaDuMYgdhjEDl3P0OcPs4vpqVdd7uHJwKeFR5SWvqAjNY4pbKKZDiULfB2MYjUK5DiMiPDhkxDYY8cs9hXREQsVmMtCqJCI8XN0lGapPkY4oIyJJCKKCQX2tY6EoInJpBjQJACl00dv66njW5fDhdfkxhW3M83NTHM3030U1NPL6_BkWFA5QOjXzehtzXRe6Yac_wwifRQ2LSu719mzv-vyxT93-RI9aP9_r9BRsSv1a3RP7otlvjuxjqkTC9gfVsXTGg |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Successful+use+of+trastuzumab+deruxtecan+in+hepatic+visceral+crisis+secondary+to+metastatic+HER2-low+breast+cancer&rft.jtitle=Current+problems+in+cancer.+Case+reports&rft.au=Kapoor%2C+Nilesh&rft.au=Su%2C+Malcolm&rft.au=Horadam%2C+Rochelle&rft.au=Klemow%2C+Dawn&rft.date=2025-12-01&rft.issn=2666-6219&rft.eissn=2666-6219&rft.volume=20&rft.spage=100392&rft.epage=100392&rft_id=info:doi/10.1016%2Fj.cpccr.2025.100392&rft.externalDBID=ECK1-s2.0-S2666621925000444&rft.externalDocID=1_s2_0_S2666621925000444 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26666219%2Fcov200h.gif |